Literature DB >> 26920466

Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence.

Adam I Cole1, Todd M Morgan1, Daniel E Spratt2, Ganesh S Palapattu3, Chang He1, Scott A Tomlins4, Alon Z Weizer3, Felix Y Feng2, Angela Wu5, Javed Siddiqui5, Arul M Chinnaiyan4, Jeffrey S Montgomery1, Lakshmi P Kunju6, David C Miller1, Brent K Hollenbeck1, John T Wei1, Rohit Mehra7.   

Abstract

PURPOSE: The importance of primary Gleason grade among men with Gleason score 7 disease has been well-defined. However, this dichotomization may oversimplify the continuous spectrum of absolute percent Gleason grade 4 disease (G4%). In this study we report the prognostic value of G4% in cancer related outcomes of men undergoing radical prostatectomy.
MATERIALS AND METHODS: Patients who underwent radical prostatectomy for clinically localized Gleason 6-8 prostate cancer from 2005 to 2013 were included in the study. G4% was determined as biopsy tumor length containing Gleason pattern 4/total tumor length, which performed better than alternative quantifications of pattern 4 involvement. G4% was correlated with time to biochemical recurrence and presence of adverse radical prostatectomy pathology, defined as primary Gleason 4 or pT3 or greater, by multivariable Cox and logistic regressions.
RESULTS: Of 1,691 patients 517 (30.6%) had adverse pathological features and 86 (5.6%) experienced biochemical recurrence. On multivariable analyses G4% was a significant predictor of adverse pathology (OR 1.04, 95% CI 1.03-1.05) and time to biochemical recurrence (HR 1.02, CI 1.01-1.03). G4% was also a significant independent predictor of adverse pathology in subsets of patients with Gleason score 7 (OR 1.05, 95% CI 1.03-1.06), 3+4 (OR 1.06, 95% CI 1.04-1.08) and 4+3 cancer (OR 1.05, 95% CI 1.03-1.06). We found a significantly increased risk of adverse pathology at potentially meaningful G4% thresholds (1% to 10% vs 20% to 30%).
CONCLUSIONS: The incremental percentage of Gleason grade 4 disease in biopsy specimens is an important predictor of adverse pathology and biochemical recurrence across the entire range of G4% disease. Accounting for G4% can improve risk assessment even among those patients with Gleason 3+4 or 4+3 cancer and may help inform patient counseling.
Copyright © 2016 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  biopsy; neoplasm grading; prostatectomy; prostatic neoplasms; recurrence

Mesh:

Year:  2016        PMID: 26920466     DOI: 10.1016/j.juro.2016.01.120

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  26 in total

1.  A Multi-scale U-Net for Semantic Segmentation of Histological Images from Radical Prostatectomies.

Authors:  Jiayun Li; Karthik V Sarma; King Chung Ho; Arkadiusz Gertych; Beatrice S Knudsen; Corey W Arnold
Journal:  AMIA Annu Symp Proc       Date:  2018-04-16

Review 2.  Active Surveillance for Intermediate Risk Prostate Cancer.

Authors:  Laurence Klotz
Journal:  Curr Urol Rep       Date:  2017-08-11       Impact factor: 3.092

3.  Presence of invasive cribriform or intraductal growth at biopsy outperforms percentage grade 4 in predicting outcome of Gleason score 3+4=7 prostate cancer.

Authors:  Charlotte F Kweldam; Intan P Kümmerlin; Daan Nieboer; Ewout W Steyerberg; Chris H Bangma; Luca Incrocci; Theodorus H van der Kwast; Monique J Roobol; Geert J van Leenders
Journal:  Mod Pathol       Date:  2017-05-19       Impact factor: 7.842

4.  Prostate biopsy characteristics: A comparison between pre- and post- United States Preventive Service Task Force Prostate Cancer Screening Guidelines of 2012.

Authors:  Navin Shah; Thomas Huebner; Vladimir Ioffe; Richard Hum
Journal:  Rev Urol       Date:  2017

5.  Correlation between cribriform/intraductal prostatic adenocarcinoma and percent Gleason pattern 4 to a 22-gene genomic classifier.

Authors:  Alexander S Taylor; Todd M Morgan; David G Wallington; Arul M Chinnaiyan; Daniel E Spratt; Rohit Mehra
Journal:  Prostate       Date:  2019-11-18       Impact factor: 4.104

6.  Frequency of Gleason score 7 to 10 in 5100 elderly prostate cancer patients.

Authors:  Navin Shah; Vladimir Ioffe
Journal:  Rev Urol       Date:  2016

Review 7.  Histopathology of Prostate Cancer.

Authors:  Peter A Humphrey
Journal:  Cold Spring Harb Perspect Med       Date:  2017-10-03       Impact factor: 6.915

8.  Risk Estimation of Metastatic Recurrence After Prostatectomy: A Model Using Preoperative Magnetic Resonance Imaging and Targeted Biopsy.

Authors:  Thomas Bommelaere; Arnauld Villers; Philippe Puech; Guillaume Ploussard; Julien Labreuche; Elodie Drumez; Xavier Leroy; Jonathan Olivier
Journal:  Eur Urol Open Sci       Date:  2022-05-19

9.  Clinical Usefulness of Total Length of Gleason Pattern 4 on Biopsy in Men with Grade Group 2 Prostate Cancer.

Authors:  Lucas W Dean; Melissa Assel; Daniel D Sjoberg; Andrew J Vickers; Hikmat A Al-Ahmadie; Ying-Bei Chen; Anuradha Gopalan; S Joseph Sirintrapun; Satish K Tickoo; James A Eastham; Peter T Scardino; Victor E Reuter; Behfar Ehdaie; Samson W Fine
Journal:  J Urol       Date:  2019-01       Impact factor: 7.450

Review 10.  Active surveillance for prostate cancer: selection criteria, guidelines, and outcomes.

Authors:  Colton H Walker; Kathryn A Marchetti; Udit Singhal; Todd M Morgan
Journal:  World J Urol       Date:  2021-03-02       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.